Ret Proto-Oncogene anticorps (Extracellular Domain)

N° du produit ABIN289533

Détail du produit anti-Ret Proto-Oncogene anticorps

Antigène: Ret Proto-Oncogene (RET)

Épitope: Extracellular Domain

Reactivité: Souris

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp Ret Proto-Oncogene est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Purification: Purified

Immunogène: Ret antibody was raised in goat using NSO derived murine ret extracellular domain as the immunogen.

Information d'application

Indications d'application: ELISA: 0.5-1 μg/mL, IHC-F: 5 μg/mL, IHC-P: 10-15 μg/mL, WB: 0.1-0.2 μg/mL
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Reconstitute with PBS.

Concentration: Lot specific

Buffer: Lyophilized from PBS, pH 7.2 containing 5 % trehalose.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: -80 °C

Stockage commentaire: Aliquot and store at -70 °C or lower.

Références pour anticorps anti-Ret Proto-Oncogene (ABIN289533)

Gay, Valenta, Herr, Paratore-Hari, Basler, Sommer: "Distinct adhesion-independent functions of β-catenin control stage-specific sensory neurogenesis and proliferation." dans: BMC biology, Vol. 13, pp. 24, (2015) (PubMed).

Aron, Klein, Pham, Kramer, Wurst, Klein: "Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons." dans: PLoS biology, Vol. 8, Issue 4, pp. e1000349, (2010) (PubMed).

Détails sur Ret Proto-Oncogene

Antigène: Ret Proto-Oncogene (RET)

Autre désignation: Ret (RET Produits)

Synonymes: anticorps c-ret, anticorps cret, anticorps etID315074.13, anticorps ret1, anticorps wu:fd13h01, anticorps X-ret, anticorps ret-A, anticorps xret, anticorps RET, anticorps MTC1, anticorps CDHF12, anticorps CDHR16, anticorps HSCR1, anticorps MEN2A, anticorps MEN2B, anticorps PTC, anticorps RET-ELE1, anticorps RET51, anticorps RET9, anticorps c-Ret, anticorps ret proto-oncogene receptor tyrosine kinase, anticorps ret proto-oncogene S homeolog, anticorps ret proto-oncogene, anticorps ret, anticorps ret.S, anticorps RET, anticorps Ret

Sujet: The Ret proto-oncogene (c-Ret) is a receptor tyrosine kinase that functions as a multicompetent receptor complex in conjunction with other membrane-bound ligand-binding GDNF family receptors. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung’s disease. The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity.

Pathways: Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation